Simple Summary L-asparaginase (L-ASNase) therapy is key for achieving the very high cure
rate of pediatric acute lymphoblastic leukemia (ALL), yet its use is mostly confined to this …

Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over
the past five decades with now over 90% of children achieving long-term survival. A direct …

Resolving conflict of interest The Joint Task Force on Practice Parameters (JTFPP) is
committed to ensuring that all guidelines are based on the best scientific evidence at the …

Polyethylene glycol (PEG) is a flexible, hydrophilic simple polymer that is physically attached
to peptides, proteins, nucleic acids, liposomes, and nanoparticles to reduce renal clearance …

PURPOSE Asparaginase is an essential drug in childhood acute lymphoblastic leukemia
(ALL) therapy and is frequently given for months to obtain continuous asparagine depletion …

Acute lymphoblastic leukemia (ALL) is a heterogenous hematological malignancy
representing 25% of all cancers in children less than 15 years of age. Significant …

Personalized medicine is focused on research disciplines which contribute to the
individualization of therapy, like pharmacogenomics and pharmacotranscriptomics. Acute …

Asparaginase treatment is a mainstay in contemporary treatment of acute lymphoblastic
leukemia (ALL), but substantial asparaginase-related toxicity may lead to jeopardized …

A wider use of L-asparaginase in the treatment of children with acute lymphoblastic
leukemia has improved cure rates during recent decades and hence led to introduction of …

Asparaginase is essential in treating acute lymphoblastic leukaemia (ALL). Asparaginase‐
related hypersensitivity causes treatment discontinuation, which is associated with …